Evidence map›Paper›PMID 38791999›Full record

ArticleCancers2024

Clinical and Genomic Features of Patients with Renal Cell Carcinoma and Advanced Chronic Kidney Disease: Analysis of a Multi-Institutional Database.

Corbin J Eule, Junxiao Hu, Dale Hedges, Alkesh Jani, Thomas Pshak, Brandon J Manley, Alejandro Sanchez, Robert Dreicer, Zin W Myint, Yousef Zakharia and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Corbin J EuleDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-8430-1040
Junxiao HuBiostatistics Core, University of Colorado Cancer Center, Aurora, CO 80045, USA.ORCID 0000-0002-5937-7916
Dale HedgesAster Insights, Hudson, NY 13610, USA.
Alkesh JaniDivision of Nephrology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Thomas PshakDivision of Urology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Brandon J ManleyDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0002-7927-1510
Alejandro SanchezDivision of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Robert DreicerDivision of Medical Oncology, Department of Medicine, University of Virginia Comprehensive Cancer Center, Charlottesville, VA 22908, USA.
Zin W MyintDivision of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.ORCID 0000-0002-3479-4203
Yousef ZakhariaDivision of Hematology, Oncology, and Blood and Bone Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-9480-2626
Elaine T LamDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-5629-3402

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA086862NCI NIH HHS P30 CA177558University of Colorado Cancer Center P30CA046934
6 · The paper itself

Abstract

backgroundPatients with advanced chronic kidney disease (ACKD) are at an increased risk of developing renal cell carcinoma (RCC), but molecular alterations in RCC specimens arising from ACKD and overall survival (OS) in affected patients are not well defined. PATIENTS AND

methodsUsing the Oncology Research Information Exchange Network (ORIEN) Total Cancer Care

resultsOf 296 patients with RCC, 61 met the criteria for ACKD. The most common somatic mutations in the overall cohort were in

conclusionsUsing the clinicogenomic ORIEN database, our study found lower rates of

Indexed as

BAP1chronic kidney diseasegenomicsmutationrenal cell carcinoma

Identifiers

PMID38791999
PMCPMC11119962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.